Zeitschrift für Bioäquivalenz und Bioverfügbarkeit

Abstrakt

Bioequivalence of Trimetazidine Modified Release Tablet Formulations Assessed in Indonesian Subjects

Yahdiana Harahap, Budi Prasaja MM, Windy Lusthom, Hardiyanti, Fahmi Azmi, Vita Felicia and Lia Yumi Yusvita

This study was conducted in order to compare the bioavailability of two modified release tablets containing 35 mg of trimetazidine. Twenty-four subjects were enrolled in a single center, randomized, single dose, open label, two-way crossover study with a one-week washout period. Plasma samples were collected up 48 hours following drug administration and trimetazidine was determined by liquid chromatography-tandem mass spectrometry (LC- MS/MS) method with turboionspray mode. Pharmacokinetic parameters used for bioequivalence assessment were AUC 0-t , AUC 0- ∞ and C max . The 90% confidence intervals obtained by analysis of variance for AUC 0-t , AUC 0- ∞ and C max were 94.89-105.15%, 94.85-105.23%, 93.31-107.36%, respectively. These results were all within the range of 80.00-125.00%. Bioequivalence between formulations was concluded both in terms of rate and extent of absorption.